Biotech firm gets £2.5m in sales from ground-breaking pre-natal test

Biotech firm gets £2.5m in sales from ground-breaking pre-natal test

Premaitha Health has reeled in £2.5m in sales in the first full year of commercialisation of its IONA non-invasive prenatal test (NIPT) for Downs Syndrome.

During the year, the company made considerable progress in establishing an initial customer base of laboratories which are now processing tests for hospitals in the UK, Poland, Switzerland, France, Russia and the Middle East.

“The international landscape for non-invasive prenatal testing is evolving very considerably in Premaitha’s favour – with numerous countries moving towards making this safer testing procedure more freely and readily available through public health services. We expect the UK to soon make NIPT freely available to high risk women on the NHS and for other countries to follow suit.”

See the article in full at BusinessDesk.com

Important information

This information is of a general nature and does not constitute an offer to provide services.

The opinions and conclusions given here are those of Seneca Partners and are subject to change without notice.

The value of investments and/or any income arising from them may fluctuate.

Past performance is not necessarily a guide to future performance.

Important notice

The products and services shown on this website place capital at risk. Investors may receive less in returns than they have invested. Investments may not allow for capital to be withdrawn on demand. If an investment provides tax relief then this relief is subject to change and is dependant on personal circumstances. Any reference to past performance or forecasted performance is not a reliable indicator of future performance.

Seneca Partners recommends that any investor seeks specialised financial and/or tax advice before investing. Seneca Partners does not provide advice and the information on this website, including but not limited to news, should not be construed as such.

Please confirm that you understand this warning and wish to proceed.